To further define the cytogenetic differences between B-cell lineage (B-lineage) acute lymphoblastic leukemia (ALL) and T-cell lineage ALL (T-ALL) and to determine the prognostic value of cytogenetics in childhood T-ALL, the blast cell karyotypes of 343 cases of pediatric T-ALL, the largest series reported to date, were evaluated. Cytogenetics were performed in a single central laboratory, and the children were treated using a single Pediatric Oncology Group protocol. Clear differences between the karyotypic characteristics of B-lineage ALL and T-ALL were confirmed. This study suggests that there may be survival differences associated with some T-ALL blast cell karyotypes. Better survival is associated with only normal karyotypes and with t(10;14) (translocation of chromosomes 10 and 14); worse survival is associated with the presence of any derivative chromosome. Two new recurring chromosome aberrations previously not reported in T-ALL were found: del(1)(p22) and t(8;12)(q13;p13). Ten aberrations found in this series, which were reported only once previously in T-ALL, can now be considered recurring abnormalities in T-ALL. All 12 of these new recurring aberrations are targets for discovery and characterization of new genes that are important in T-cell development and leukemogenesis.

The clinical utility of cytogenetic evaluation of leukemic blasts is nowhere better exemplified than in childhood acute lymphoblastic leukemia (ALL). The independent prognostic importance of blast cell karyotypes (eg, the good prognosis associated with hyperdiploidy in contrast to the poor prognosis associated with several specific translocations) is so well established that the karyotype has been used during the past decade for the accurate assignment of risk and selection of risk-directed therapy for patients with ALL.1-5 The data, however, that established the blast cell chromosome number as an independent prognostic indicator in childhood ALL did not distinguish between B-cell and T-cell lineage ALL (B-lineage ALL and T-ALL, respectively). The most frequently occurring clinically important translocations in ALL, such as t(9;22), t(1;19), and t(4;11), are associated primarily with B-lineage ALL.

T-ALL comprises 12%-15% of childhood ALL. T-ALL has clinical, biochemical, immunologic, and chromosomal features that are distinct from those of B-lineage ALL.6-10 Because most children with ALL have been stratified and treated without regard to immunophenotype, evaluation of the prognostic importance of clinical or laboratory variables in T-ALL has been difficult. To address this problem, the Pediatric Oncology Group (POG) adopted the strategy of treating children with T-ALL with a common, aggressive protocol, as described elsewhere,11 that included cytogenetic evaluation of blast cells at diagnosis. The blast cell karyotypes of this large series of childhood T-ALL patients were analyzed to further define the cytogenetic differences between B-lineage ALL and T-ALL and to determine the prognostic value of cytogenetics in childhood T-ALL.

Patients

From January 1986 to January 1992, 439 eligible children (ages, at least 1 year to less than 22 years) with newly diagnosed T-ALL were entered in POG study 8691 (the pilot study for study 8704) or 8704. Diagnosis of T-ALL was made according to the morphological and cytochemical criteria of the French-American-British classification and by immunophenotyping. All patients were treated with an intensive 7-drug protocol. The total duration of therapy was 2 years. The patients were randomly assigned to receive weekly doses of L-asparaginase during initial maintenance therapy. The cut-off date for analysis was October 21, 1998.

Cytogenetic evaluation

Bone marrow samples for cytogenetic evaluation were obtained before initiation of therapy and shipped overnight to a single laboratory at the University of Alabama at Birmingham. Routine methods were employed for overnight culture, harvest, slide preparation, and G-banding with trypsin and Wright's stain. Whenever possible, a minimum of 20 metaphase cells were analyzed for each sample. A minimum of 10 metaphase cells were analyzed before reporting a normal karyotype. Chromosome abnormalities were described according to the International System for Human Cytogenetic Nomenclature.12 

Statistical methods

This study is mainly descriptive. Event-free survival is defined as the time from registration to first event among failures (failure to achieve remission, relapse, second cancer, or death) or time from registration to last clinical contact (nonfailures). Comparisons of subgroups were done by both univariate methods (log-rank test13) and multivariate methods (Cox proportional hazards model14). Four-year estimates of event-free survival were constructed by the method of Kaplan-Meier,15 using SEs of Peto and coworkers.13 Statistical analyses were not done for clinical correlates because the standards for clinical significance are much greater than for statistical significance in this area.

Patient characteristics

The age, race, sex ratio, white blood cell (WBC) count, and survival characteristics of groups of patients with successful cytogenetic evaluations are shown in Table1. The median age, racial distribution, and median WBC count at diagnosis for this series of patients are typical for childhood T-ALL and in general do not differ substantially by karyotype.

Table 1.

Clinical features and outcomes according to karyotype

Patients, no.Median age, y (quartiles)Race, %Sex, M:FMedian WBC, ×103/μL (quartiles)FailedExpectedP
White/OtherBlackHispanic
Total 354 8.2  (5.3-12.6) 76.6 15 3.0 70  (19-189)   —  
Normal karotype 153 8.2  (5.4-12.9) 77 16 3.1 78  (19-196) 68 83.7 .019  
Abnormal karotype 201 8.3  (5.2-11.9) 77 14 2.9 62  (19-188) 114 98.3 —  
Hypodiploid 16 7.9  (5.7-10.0) 68 19 13 4.3 76  (15-107) 12 9.0 .63  
Pseudodiploid 124 7.8  (4.8-11.8) 75 15 10 4.0 66  (21-233) 67 72.2 —  
Hyperdiploid,
47-50 chrom. 
47 8.5  (5.4-13.2) 78 13 2.1 60  (16-161) 26 25.5 —  
Hyperdiploid,
>50 chrom. 
14 8.5  (7.1-12.3) 86 0.75 21  (11-71) 7.3 —  
Any translocation 122 7.8  (4.8-11.9) 70 19 11 2.7 65  (20-189) 66 70.1 .43  
Any del chrom. 91 8.5  (4.9-11.8) 75 13 12 3.3 60  (20-199) 57 64.9 .14  
Any der chrom. 51 9.8  (5.3-14.0) 72 20 2.4 77  (14-202) 35 25.7 .037  
Any 14q11-13 abnormality 43 8.2  (4.7-13.7) 65 19 16 4.4 85  (25-391) 19 27.0 .08  
Del(6q) 38 8.8  (5.0-11.3) 76 11 13 4.4 75  (39-340) 27 20.0 .087  
+8 22 7.0  (4.2-12.9) 86 14 1.8 56  (10-154) 12 11.0 .76  
Loss of 9p* 32 9.0  (6.3-12.8) 78 13 3.0 83  (26-219) 16 18.3 .56  
t(11;14) 14 6.8  (4.1-11.8) 72 21 2.5 407  (58-466) 7.8 .94 
t(10;14) 12 7.5  (5.1-9.4) 67 33 5.0 54  (14-130) 9.7 .024  
Loss of 5q 19 7.4  (4.5-11.1) 63 26 11 3.8 19  (3-96) 15 8.5 .067 
Patients, no.Median age, y (quartiles)Race, %Sex, M:FMedian WBC, ×103/μL (quartiles)FailedExpectedP
White/OtherBlackHispanic
Total 354 8.2  (5.3-12.6) 76.6 15 3.0 70  (19-189)   —  
Normal karotype 153 8.2  (5.4-12.9) 77 16 3.1 78  (19-196) 68 83.7 .019  
Abnormal karotype 201 8.3  (5.2-11.9) 77 14 2.9 62  (19-188) 114 98.3 —  
Hypodiploid 16 7.9  (5.7-10.0) 68 19 13 4.3 76  (15-107) 12 9.0 .63  
Pseudodiploid 124 7.8  (4.8-11.8) 75 15 10 4.0 66  (21-233) 67 72.2 —  
Hyperdiploid,
47-50 chrom. 
47 8.5  (5.4-13.2) 78 13 2.1 60  (16-161) 26 25.5 —  
Hyperdiploid,
>50 chrom. 
14 8.5  (7.1-12.3) 86 0.75 21  (11-71) 7.3 —  
Any translocation 122 7.8  (4.8-11.9) 70 19 11 2.7 65  (20-189) 66 70.1 .43  
Any del chrom. 91 8.5  (4.9-11.8) 75 13 12 3.3 60  (20-199) 57 64.9 .14  
Any der chrom. 51 9.8  (5.3-14.0) 72 20 2.4 77  (14-202) 35 25.7 .037  
Any 14q11-13 abnormality 43 8.2  (4.7-13.7) 65 19 16 4.4 85  (25-391) 19 27.0 .08  
Del(6q) 38 8.8  (5.0-11.3) 76 11 13 4.4 75  (39-340) 27 20.0 .087  
+8 22 7.0  (4.2-12.9) 86 14 1.8 56  (10-154) 12 11.0 .76  
Loss of 9p* 32 9.0  (6.3-12.8) 78 13 3.0 83  (26-219) 16 18.3 .56  
t(11;14) 14 6.8  (4.1-11.8) 72 21 2.5 407  (58-466) 7.8 .94 
t(10;14) 12 7.5  (5.1-9.4) 67 33 5.0 54  (14-130) 9.7 .024  
Loss of 5q 19 7.4  (4.5-11.1) 63 26 11 3.8 19  (3-96) 15 8.5 .067 

The expected outcome is the log-rank that is anticipated under the hypothesis that there is no difference in target population survival curves. The P values for specific abnormalities are compared to others with abnormal karyotypes.

*

Includes del(9p), der(9) with loss of 9p material, and −9.

Includes del(5q), der(5) with loss of 5q material, and −5.

There were 70 patients with unsuccessful cytogenetic studies who did not differ substantially from those with successful cytogenetic evaluations (data not shown) except that their median WBC count was 145×109/L (145 000/μL) (quartiles, 48 000-435 000). This was more than twice the WBC count of those patients with successful cytogenetic evaluations whose median WBC count was 70×109/L (70 000/μL) (quartiles, 19 000-189 000). The reason for this difference is not apparent.

Table 1 suggests that children whose blast cell karyotype contains any kind of derivative chromosome (ie, an unbalanced translocation or complex rearrangement) may be somewhat older and that t(11;14) may be associated with a younger age at diagnosis. The data also show that the proportion of girls with hyperdiploid karyotypes or with an extra chromosome 8 (+8) is higher than in other karyotype groups, and that the proportion of boys with t(10;14) is higher than in other karyotype groups. A higher median WBC count is associated with t(11;14), and a lower median WBC count is associated with hyperdiploidy of more than 50 chromosomes and a loss of chromosome 5 long arm (5q) material. The number of patients in several of the karyotype categories is relatively small, however, and hence, any associations or lack thereof need to be confirmed by study of additional series of patients.

Frequency of chromosome abnormalities

Of 439 eligible patients with childhood T-ALL registered in 1 of the 2 POG studies, only 15 patients (3.4%) did not have a sample sent for cytogenetic evaluation. Of the 424 patients who had a sample sent, 70 patients (16.5%) had an unsuccessful cytogenetic evaluation. Of the 354 successfully karyotyped patients, only normal karyotypes were found in 153 patients (43.2%). Of these 153 patients, 31 (20%) had less than 20 metaphases (10-19) available for analysis. Of the 201 patients (56.8%) with an abnormal karyotype, 180 patients (89.6%) had at least one structural chromosome abnormality. All of the recurring numerical and structural chromosome abnormalities among the 201 abnormal karyotypes in this series of childhood T-ALL patients are shown in Table 2. The frequencies of some of the cytogenetic abnormalities in this series are compared in Table3 with the frequencies reported in smaller series of karyotyped T-ALL patients.10 16-24 A list of each abnormal karyotype in this series is available on the POG website (http://www.pog.ufl.edu/publ/news/T-ALL_ka.pdf).

Table 2.

Recurring chromosome abnormalities in this series

Cases, no.Abnormal karotype, % (n = 201)AbnormalitiesLoci affected
38 18.9 del(6q) D6S24652; D6S28353 
22 10.9 +8* 
14 7.0 t(11;14)(p13;q11) LMO2/RBTN2/TTG2, TCRA/D9 
12 6.0 t(10;14)(q24;q11), del(9p) TCL3/HOX11, TCRA/D9; p16/CDKN2A, P15/CDKN2B9 
11 5.5 del(5q) 
10 5.0 +21 (8/10 have Down's syndrome) 
4.5 del(11q), del(12p) U; ?TEL/ETV654 
4.0 +19 U  
3.5 del(9q), i(9q) ?GAS155; U  
3.0 +7, del(7q), del(13q) U; U; ?RB19 
2.5 t(1;14)(p34;q11), −9 SCL/TCL5/TAL1, TCRD9; ?p16/CDKN2A, ?p15/CDKN2B9 
2.0 +4, +9, t(10;11)(p13-15;q13-21), +17 U; U; AF10, CALM56; U 
1.5 dup(2)(q21-32q31-37), inv(7)(p15q34-36), t(8;14)(q24;q11), t(9;22)(q34;q11), t(11;19)(q23;p13), +20, −Y U; TCRG, TCRB57; CMYC, TCRA9; ABL, BCR58; MLL, ENL54; U; U 
1.0 del(1)(p22), del(5)(p13), +6, i(7q), t(7;10)(q34-35;q24), del(7)(p13-15), t(8;12)(q13;p13), +10, +11, der(12)t(7;12)(q11;p11), inv(12)(p12q15-21), t(12;13)(p11-12;q12), +14, i(17q), +18, +22 U; U; U; U; TCRB, TCL3/HOX1154; U; U, ?TEL/ETV6; U; U; U; U, ?HMGIC59; ?TEL/ETV6; CDX260; U; ?P539; U; U 
Cases, no.Abnormal karotype, % (n = 201)AbnormalitiesLoci affected
38 18.9 del(6q) D6S24652; D6S28353 
22 10.9 +8* 
14 7.0 t(11;14)(p13;q11) LMO2/RBTN2/TTG2, TCRA/D9 
12 6.0 t(10;14)(q24;q11), del(9p) TCL3/HOX11, TCRA/D9; p16/CDKN2A, P15/CDKN2B9 
11 5.5 del(5q) 
10 5.0 +21 (8/10 have Down's syndrome) 
4.5 del(11q), del(12p) U; ?TEL/ETV654 
4.0 +19 U  
3.5 del(9q), i(9q) ?GAS155; U  
3.0 +7, del(7q), del(13q) U; U; ?RB19 
2.5 t(1;14)(p34;q11), −9 SCL/TCL5/TAL1, TCRD9; ?p16/CDKN2A, ?p15/CDKN2B9 
2.0 +4, +9, t(10;11)(p13-15;q13-21), +17 U; U; AF10, CALM56; U 
1.5 dup(2)(q21-32q31-37), inv(7)(p15q34-36), t(8;14)(q24;q11), t(9;22)(q34;q11), t(11;19)(q23;p13), +20, −Y U; TCRG, TCRB57; CMYC, TCRA9; ABL, BCR58; MLL, ENL54; U; U 
1.0 del(1)(p22), del(5)(p13), +6, i(7q), t(7;10)(q34-35;q24), del(7)(p13-15), t(8;12)(q13;p13), +10, +11, der(12)t(7;12)(q11;p11), inv(12)(p12q15-21), t(12;13)(p11-12;q12), +14, i(17q), +18, +22 U; U; U; U; TCRB, TCL3/HOX1154; U; U, ?TEL/ETV6; U; U; U; U, ?HMGIC59; ?TEL/ETV6; CDX260; U; ?P539; U; U 

U, unknown.

*

1 case had +8,+8.

2 cases had +19,+19.

Table 3.

Frequency of selected chromosome abnormalities in this and other studies of T-ALL

Current studyHeerema et al10GFCH163-150Raimondi et al17GFCH183-150Berger et al19Kaneko et al20Gladstone et al21Secker-Walker et al22Uckun et al233-150Rowley et al24
 2000 1998 1996 1988 1993 1990 1989 1998 1992 1989 1999 
Total karyotyped 354 169C 95A 57C 56C 44A,C 33C 30A,C 19A,C 26C 15A,C 
 Normal, no. (% of total) 153 (43) 66 (39) 23 (24) 16 (28) 22 (39) 11 (25) 9 (27) 3 (10) 4 (21) 12 (46) 5 (33) 
 Abnormal, No. 201 103 72 41 34 33 24 27 15 14 10 
Chromosomal abnormalities, %            
 14q11-133-151 21.9 28 34.7 15 11.8 21 42 6.6 47 29 10 
 del(6q) 18.9 30 19.43-152 22 263-152 12 25 40 13 22 40 
 +8 10.9 10.7 5.6 2.4 NR — 3.3   — NR —  
 del(9p), incl. i(9q) 9.5 14.6 20.83-152 20 293-152 17 10 13 30 
 7q32-36 7.5 7.8 NR 2.9 — 10 20 
 t(11;14)(p13;q11) 7.0 12.6 NR 7.3 5.9 21 6.6 14 10 
 t(10;14)(q24;q11) 6.0 2.9 18.1 2.4 2.9 —  — — —  
 del(5q) 5.5 1.9 NR 2.4 11.8 3.3   —   — 10 
 del(11q) 4.5 5.8 NR 7.3 NR — 6.6   — —  
 del(12p) 4.5 3.9 5.63-152 5.93-152 24 6.6   — 14 10 
 7p15 3.9 NR 2.4 — 12.5 —   — 10 
 14q32 8.7 NR 2.4 NR 10   — 30 
Current studyHeerema et al10GFCH163-150Raimondi et al17GFCH183-150Berger et al19Kaneko et al20Gladstone et al21Secker-Walker et al22Uckun et al233-150Rowley et al24
 2000 1998 1996 1988 1993 1990 1989 1998 1992 1989 1999 
Total karyotyped 354 169C 95A 57C 56C 44A,C 33C 30A,C 19A,C 26C 15A,C 
 Normal, no. (% of total) 153 (43) 66 (39) 23 (24) 16 (28) 22 (39) 11 (25) 9 (27) 3 (10) 4 (21) 12 (46) 5 (33) 
 Abnormal, No. 201 103 72 41 34 33 24 27 15 14 10 
Chromosomal abnormalities, %            
 14q11-133-151 21.9 28 34.7 15 11.8 21 42 6.6 47 29 10 
 del(6q) 18.9 30 19.43-152 22 263-152 12 25 40 13 22 40 
 +8 10.9 10.7 5.6 2.4 NR — 3.3   — NR —  
 del(9p), incl. i(9q) 9.5 14.6 20.83-152 20 293-152 17 10 13 30 
 7q32-36 7.5 7.8 NR 2.9 — 10 20 
 t(11;14)(p13;q11) 7.0 12.6 NR 7.3 5.9 21 6.6 14 10 
 t(10;14)(q24;q11) 6.0 2.9 18.1 2.4 2.9 —  — — —  
 del(5q) 5.5 1.9 NR 2.4 11.8 3.3   —   — 10 
 del(11q) 4.5 5.8 NR 7.3 NR — 6.6   — —  
 del(12p) 4.5 3.9 5.63-152 5.93-152 24 6.6   — 14 10 
 7p15 3.9 NR 2.4 — 12.5 —   — 10 
 14q32 8.7 NR 2.4 NR 10   — 30 

A, adults; C, children; NR, not reported.

F3-150

Full karyotypes are not reported.

F3-151

Includes cases of t(11;14) and t(10;14).

F3-152

The study reported “6q abn”, “9p abn”, or “12p abn”.

Abnormalities of ploidy

Of the 201 patients with abnormal karyotypes, 16 patients (8%) were hypodiploid, 125 patients (62.2%) were pseudodiploid, 46 patients (22.9%) were hyperdiploid with 47-50 chromosomes, and 14 patients (7%) were hyperdiploid with more than 50 chromosomes. All of the hypodiploid cases had 43-45 chromosomes; none had a near-haploid karyotype. Of the 14 cases with more than 50 chromosomes, 10 had near-tetraploid karyotypes. The frequencies of ploidy groups in this series are compared in Table 4 with the frequencies reported in pediatric non–T-ALL and in other series of karyotyped T-ALL patients.

Table 4.

Frequency of ploidy groups

Non-T
ALL4-150
T
ALL4-150
Current
study
Heerema
et al10
GFCH16Raimondi
et al17
GFCH18Berger
et al19
Kaneko
et al20
Gladstone
et al21
Secker-Walker
et al22
Uckun
et al23
   2000 1998 1996 1988 1993 1990 1989 1998 1992 1989 
Near-haploid <14-151 <1 — — — — — — — — — NR 
Hypodiploid 7.5 4.3 4.5 2.4 3.5 7.1 6.8 6.1 63.3 — 3.8% 
Pseudodiploid 38.1 58.3 35.3 47.3 45 65 44.6 59 66.7 20 68.4 46 
47-50 chrom. 17.5 4.9 13 10.1 22 3.5 7.1 13.6 — — 10.5 — 
>50 chrom. 31.8 1.2 6 1.8 5.4 2.3 — 6.6 — 3.8 
Normal 4.8 24.5 43.2 39.1 24 28 39 25 27 10 21 46 
Non-T
ALL4-150
T
ALL4-150
Current
study
Heerema
et al10
GFCH16Raimondi
et al17
GFCH18Berger
et al19
Kaneko
et al20
Gladstone
et al21
Secker-Walker
et al22
Uckun
et al23
   2000 1998 1996 1988 1993 1990 1989 1998 1992 1989 
Near-haploid <14-151 <1 — — — — — — — — — NR 
Hypodiploid 7.5 4.3 4.5 2.4 3.5 7.1 6.8 6.1 63.3 — 3.8% 
Pseudodiploid 38.1 58.3 35.3 47.3 45 65 44.6 59 66.7 20 68.4 46 
47-50 chrom. 17.5 4.9 13 10.1 22 3.5 7.1 13.6 — — 10.5 — 
>50 chrom. 31.8 1.2 6 1.8 5.4 2.3 — 6.6 — 3.8 
Normal 4.8 24.5 43.2 39.1 24 28 39 25 27 10 21 46 
F4-150

These numbers represent childhood ALL and were calculated from Pui et al.3 

F4-151

Percent of total karyotyped.

All were near-tetraploid.

Abnormalities of chromosome structure

Twenty-eight structural chromosome aberrations occurred more than once in this series. Genes known or likely to be affected by these abnormalities are listed in Table 2. In this series, 60 patients (30% of those with abnormal karyotypes) contained a rearrangement at one or more of the chromosome bands (7p15, 7q32-36, and/or 14q11-13) that are the locations of T-cell receptor chain genes. Rearrangements in the 14q11-13 region, in which the T-cell receptor α/δ chain genes are located, were present in 21% of the karyotypically abnormal cases in this series; these aberrations included not only the relatively common and T-cell–specific translocations t(11;14)(p13;q11) and t(10;14)(q24;q11) but also a variety of other balanced and unbalanced translocations, deletions, and inversions.

New recurring cytogenetic abnormalities

Five new recurring abnormalities in this series that have not, to our knowledge, been reported as recurring aberrations in T-ALL are presented in Table 5. Chromosome abnormalities that were observed only once in this series but that have been reported once in other cases of T-ALL and thus can be designated new recurring aberrations in T-ALL are shown in Table6.

Table 5.

New recurring chromosome abnormalities in childhood T-ALL

AbnormalityCases in this series, no.Karyotypes of cases
del(1)(p22) 45,XY,del(1)(p22),-5,der(5)t(5;5)
(q13;q11),del(7)(q22q34) 
  45,XY,+del(1)(p22),der(2)t(2;17)
(p25;q21),-9,-17 
dup(2)(q21-32q31-37) 46,XY,dup(2)(q31q37) 
  47,XY,t(1;18)(q32;q24),
dup(2)(q21q31),+3 
  46,Y,der(X)ins(X;?)(p11;?),
dup(2)(q21q33),del(10)(p11p13),
der(16)t(1;16)(q12;p13) 
t(8;12)(q13;p13) 46,XY,t(8;12)(q13;p13) 
  46,XX,t(8;12)(q13;p13),r(16)(p13q24) 
+9 35-150 47,XY,+9  
  48,XY,+7,+9,t(10;14)(q24;q11) 
  51,XX,+X,add(3)(q27),+6,+del
(7)(q34),+9,del(11)(q23),i(17q),+21 
del(13)(q) 55-150 46,XY,del(13)(q14q32) 
  46,XY,del(13)(q14q32) 
  46,XX,del(5)(q13),del(12)(p12),
del(13)(q14) 
  46,XY,t(5;7)(p13;q36),t(10;14)(q24;q11)
/46,idem,del(13)(q14q32) 
  46,XY,add(7)(q34),t(10;12)(q22;q24),
del(13)(q12q14) 
AbnormalityCases in this series, no.Karyotypes of cases
del(1)(p22) 45,XY,del(1)(p22),-5,der(5)t(5;5)
(q13;q11),del(7)(q22q34) 
  45,XY,+del(1)(p22),der(2)t(2;17)
(p25;q21),-9,-17 
dup(2)(q21-32q31-37) 46,XY,dup(2)(q31q37) 
  47,XY,t(1;18)(q32;q24),
dup(2)(q21q31),+3 
  46,Y,der(X)ins(X;?)(p11;?),
dup(2)(q21q33),del(10)(p11p13),
der(16)t(1;16)(q12;p13) 
t(8;12)(q13;p13) 46,XY,t(8;12)(q13;p13) 
  46,XX,t(8;12)(q13;p13),r(16)(p13q24) 
+9 35-150 47,XY,+9  
  48,XY,+7,+9,t(10;14)(q24;q11) 
  51,XX,+X,add(3)(q27),+6,+del
(7)(q34),+9,del(11)(q23),i(17q),+21 
del(13)(q) 55-150 46,XY,del(13)(q14q32) 
  46,XY,del(13)(q14q32) 
  46,XX,del(5)(q13),del(12)(p12),
del(13)(q14) 
  46,XY,t(5;7)(p13;q36),t(10;14)(q24;q11)
/46,idem,del(13)(q14q32) 
  46,XY,add(7)(q34),t(10;12)(q22;q24),
del(13)(q12q14) 
F5-150

One case with a near-triploid complex karyotype is not included.

Table 6.

Single observations in this study that are new recurring chromosome abnormalities in childhood T-ALL

ObservationsReferences
This studySimilar in another study
del(4)(p15) del(4)(p14) Raimondi et al,17 case 53 
t(4;11)(q21;p13) t(4;11)(q21;p14-15 Hardingham et al61 
dic(7;9)(p11;p11) dic(7;9)(p11;p11) Diaz et al,62 case 17  
del(8)(p21) del(8)(p21) Raimondi et al,17 case 21 
inv(11)(p13p15) inv(11)(p11p15.2) Hayashi et al,25 case 42  
+11 +11 Heerema et al,10 case 101 
inv(12)(p12q21) inv(12)(p13q22) Raimondi et al,17 case 20 
ObservationsReferences
This studySimilar in another study
del(4)(p15) del(4)(p14) Raimondi et al,17 case 53 
t(4;11)(q21;p13) t(4;11)(q21;p14-15 Hardingham et al61 
dic(7;9)(p11;p11) dic(7;9)(p11;p11) Diaz et al,62 case 17  
del(8)(p21) del(8)(p21) Raimondi et al,17 case 21 
inv(11)(p13p15) inv(11)(p11p15.2) Hayashi et al,25 case 42  
+11 +11 Heerema et al,10 case 101 
inv(12)(p12q21) inv(12)(p13q22) Raimondi et al,17 case 20 

Karyotype and survival

The series follow-up was excellent. In the first 5 years, only 14 patients were lost to follow-up (4 patients with an abnormal karyotype, 9 with a normal karyotype, and 1 with an unsatisfactory cytogenetic study). The actuarial 5-year event-free survivals by karyotype group were: 51% of those with an abnormal karyotype (4% SE); 62% of those with a normal karyotype (4% SE); and 60% of those who had unsatisfactory results (6% SE). The Cox analysis, which questioned if, taken together, any of the 11 variables listed in Table 1 were associated with the outcome, resulted in P = .16. Given the inconclusive nature of this overall result, those analyses that are univariately significant in Table 1 should be viewed as promising, but they require confirmation from another series study prior to consideration of any of those associations as definitive.

The present study is not only the largest reported series of karyotyped cases of pediatric T-ALL, but it is also the largest series of childhood T-ALL cases karyotyped in a single laboratory and treated with a single protocol. While this series failed to produce definitive associations between karyotypic features and event-free survival, it uncovered several karyotypic abnormalities needing further investigation concerning such an association. In contrast to pediatric B-lineage ALL, we were unable to demonstrate in childhood T-ALL a significant association between a hyperdiploid karyotype and a favorable outcome, a finding in agreement with that of Heerema et al.10 

Although this series contains a higher percentage of cases with only normal karyotypes than any other series of T-ALL cases except that of Uckun et al,23 inspection of Table 3 shows that the frequency and distribution of the abnormalities found are fairly similar to those in other series of childhood T-ALL cases. This similarity suggests that there were no karyotypic subsets of T-ALL that disproportionately failed to produce abnormal metaphases in the present series. The reason for the higher percentage of only normal karyotypes in this series is unclear. The great majority of samples in this series were sent by overnight express to a central cytogenetics laboratory; the same was true, however, for the majority of samples evaluated by Kaneko et al,20 who reported only 27% of cases with normal karyotypes. Therefore, a delay in specimen processing is unlikely to be the reason. If all 31 patients in this series with a normal karyotype based on fewer than 20 metaphases were assumed to have an undetected cytogenetically abnormal clone, then the proportion of patients in this series with a normal karyotype would be 34.5%, a figure closer to that reported in other studies.

The results of this series confirm that t(11;14)(p13;q11) is the most frequently occurring translocation in childhood T-ALL and are consistent with results of most other studies regarding the frequency of other T-cell receptor chain gene-related aberrations such as t(10;14)(q24;q11) and rearrangements involving 7q32-34 or 7p15. One large study of adult ALL patients16 found that t(10;14), not t(11;14), was the most frequent translocation in adult T-ALL, and that the frequency of 14q11 breakpoints was higher than in childhood ALL. In the series reported by Heerema et al,10 patients with 14q11 breakpoints had a higher WBC count than patients in other karyotype groups; in our series, however, only the t(11;14) patients had a substantially higher median WBC count than other karyotype groups.

The single most common chromosome abnormality in this series, present in nearly 1 case in 5, was del(6q). This abnormality was found in only 10% of a large series of cases of childhood ALL of all types by Hayashi et al.25 The present series, as well as others in Table 3, suggest that del(6q) is more common in T-ALL than in childhood ALL in general, a finding reported by the Groupe Français de Cytogenetique Hematologique (GFCH) in their large series of karyotyped childhood ALL cases, which included 56 T-ALL patients.18In this series, similar to the findings of Heerema et al,10 del(6q) was the sole aberration in 26% of the patients with a del(6q), and no common deleted region was apparent.

The frequency of cases with +8 is virtually the same in this series and that of Heerema et al,10 although the frequency of +8 reported in other series is lower. The results of this series confirm that +8 is more common in T-ALL than in B-lineage ALL.26,27 Of 21 patients with +8 in this series, +8 was the sole chromosome abnormality in 6 patients (4 of whom were reported previously by Pettenati et al26), thereby comprising 3% of all cases with an abnormal karyotype. In 2 cases in this series, +8 was associated with t(11;19)(q23;p13.3) as the only other chromosome abnormality. Trisomy 8 and t(11;19)(q23;p13) also occur together in acute myeloid leukemia, suggesting that these 2 chromosome abnormalities tend to arise in a multipotent cell.28 

A difference between the findings of this study and those of the 4 next-largest studies is that our series has a lesser frequency of cases with del(9p) or i(9q). When cases with a loss of a whole chromosome 9 or with an unbalanced rearrangement resulting in a loss of 9p material are added to cases with del(9p) and i(9q), the proportion of cases with loss of all or part of 9p in this series is 15.4%, which is comparable to the proportion of cases with a loss of 9p that was reported by Heerema et al.10 Murphy et al29found deletions of 9p significantly more often in childhood T-ALL than in non–T-ALL (15.7% vs 6.2%, respectively). The GFCH18found that 9p abnormalities were associated more often with T-ALL than with non–T-ALL, but the difference was not statistically significant. In this series, like that of Heerema et al,10 bands 9p22-24 appeared to be missing in all cases with a loss of the 9p material. The p15 and p16 genes, which are often deleted or inactivated in pediatric T-ALL,30 are on 9p.

The percentage of patients (5.5%) with a del(5q) is comparable to frequencies that have been reported in other series of T-ALL (Table 3). Although del(5q) is common in myeloid neoplasms, it is distinctly uncommon in ALL. In 1992, Theodossiou et al31 reported 3 ALL patients with del(5q) and found only 23 such patients reported in the literature; interestingly, 10 of the 19 phenotyped patients had T-ALL. The following year, the GFCH18 reported aberrations in the 5q31-35 region in 4 of 56 pediatric T-ALL patients, a proportion comparable to the findings in this and other studies of T-ALL patients.

Recurring and/or well characterized chromosome abnormalities in T-ALL that were not seen in this series include t(5;14)(q33-34;q11)32; t(7;9)(q34;q32); t(7;9)(q34;q34.3); t(7;19)(q34;p13)33; t(7;11)(q35;p13)10,34; and inv(14)(q11q32).10,35,36 Some structural aberrations that were observed only once in this series and are known to be rare recurring abnormalities in T-ALL include t(1;7)(p34;q32)10,17,23,33; t(1;11)(p34-36;p11-13)16,17; t(11;14)(p15;q11)10,37,38; inv(5)(p11q13)10,17; and del(17)(p11).10 22 

Five recurring chromosome abnormalities in this series have not been previously reported as recurring aberrations in T-ALL (Table 5), although all 5 have been reported in unphenotyped cases or in other types of ALL, and 3 have been reported in single cases of T-ALL. These abnormalities, which are described further below, are del(1)(p22); dup(2)(q21-32q31-37); t(8;12)(q13;p13); +9; and del(13)(q).

del(1)(p22)

Two patients with ALL have been reported with del1(p22); one patient had common ALL,1 and the other had an unclear immune phenotype.39 

dup(2)(q21-32q31-37)

The report by Murphy et al29 that includes some T-ALL cases describes a case with dup(2q), but the immune phenotype of that case was not reported. Two other cases with dup(2q) have been reported,40,41 but they were without immune phenotypes. One case of T-ALL with dup(2)(q11.2q31) has been reported.10 

t(8;12)(q13;p13)

Only 1 reported case of t(8;12)(q13;p12-13), a case of common ALL, was found.40 

+9

Several cases of common ALL,23,42-44 mixed-lineage ALL,45 and unphenotyped ALL46,47 with +9 in a karyotype with no more than 51 chromosomes have been reported, but only one of these cases had T-ALL.10 

del(13)(q)

Cases of common ALL40,48,49 or unphenotyped ALL29,50 with del(13q) have been reported, but only one case was reported with T-ALL10; a molecular deletion in 13q was reported in one T-ALL cell line.49 Del(13q) is common in chronic lymphoid leukemia (CLL),51 and it may be an important step in the development of lymphoid leukemias of various types. That it may be an early or primary cytogenetic event is confirmed by 2 cases in this series with del(13q) as a sole chromosomal abnormality.

Out of 5 new recurring chromosome abnormalities in T-ALL in this series, 4 occurred as a sole abnormality in at least one case, which suggests that the abnormalities may be early or primary events in leukemogenesis. The fact that each has been observed in non–T-ALL indicates that these abnormalities are not specific for T-cell leukemogenesis.

Seven of the single observations in this series have been reported only once previously in T-ALL to our knowledge. Together with those single previous reports, our observation of another case in this series defines those aberrations as additional rare recurring chromosome abnormalities in T-ALL (Table 6).

Conclusion

In all, this study has identified 12 new recurring cytogenetic aberrations in T-ALL. This series confirms that the karyotypic characteristics of childhood T-ALL are clearly different from those of B-lineage childhood ALL, supporting the notion that B-lineage ALL and T-ALL are biologically distinct neoplasms. Not only are the types and frequencies of chromosomal abnormalities very different in B-lineage ALL and T-ALL, but the contrast between the prognostic importance of blast karyotype in childhood B-lineage ALL versus its relative lack of importance in T-ALL is striking. Hyperdiploidy of 51-60 chromosomes, present in the leukemic blasts of about 25% of B-lineage pediatric ALL patients and associated with a good to excellent prognosis, is very uncommon in T-ALL and, when present, is not associated with any survival advantage. The recurring translocations of B-lineage ALL are very rarely seen in childhood T-ALL, whereas the 2 most common translocations in T-ALL, t(11;14) and t(10;14), are virtually never seen in B-lineage ALL. Most recurring translocations in B-lineage ALL are or have been associated with a poor prognosis, whereas t(10;14) in T-ALL may be associated with a higher rate of survival. The longer survival associated with t(10;14) was first reported in adult T-ALL16 and is confirmed (by univariate analysis only) in this large series of pediatric T-ALL.

Supported by grants CA-03161, CA-53128, CA-69177, CA-29691, CA-07431, CA-41573, CA-15525, CA-69428, CA-20549, CA-28476, CA-33587, CA-11233, CA-29293, CA-28383, CA-33625, CA-31566, CA-33603, CA-29139, CA-25408, CA-15989, CA-28439, and CA-05587 from the National Institutes of Health, Bethesda, MD.

Submitted October 19, 1999; accepted June 6, 2000.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Secker-Walker
 
LM
Chessells
 
JM
Stewart
 
EL
Swansbury
 
GJ
Richards
 
S
Lawler
 
SD
Chromosomes and other prognostic factors in acute lymphoblastic leukaemia: a long-term follow-up.
Br J Haematol.
72
1989
336
342
2
Bloomfield
 
CD
Secker-Walker
 
LM
Goldman
 
AI
et al
Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia.
Cancer Genet Cytogenet.
40
1989
171
185
3
Pui
 
CH
Crist
 
WM
Look
 
AT
Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia.
Blood.
76
1990
1449
1463
4
Raimondi
 
SC
Current status of cytogenetic research in childhood acute lymphoblastic leukemia.
Blood.
81
1993
2237
2251
5
Cortes
 
JE
Kantarjian
 
HM
Acute lymphoblastic leukemia: a comprehensive review with emphasis on biology and therapy.
Cancer.
76
1995
2393
2417
6
Pui
 
CH
Behm
 
FG
Singh
 
B
et al
Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia.
Blood.
75
1990
174
179
7
Shuster
 
JJ
Falletta
 
JM
Pullen
 
J
et al
Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Blood.
75
1990
166
173
8
Pui
 
CH
Behm
 
FG
Crist
 
WM
Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia.
Blood.
82
1993
343
362
9
Uckun
 
FM
Sensel
 
MG
Sun
 
L
et al
Biology and treatment of childhood T-lineage acute lymphoblastic leukemia.
Blood.
91
1998
735
746
10
Heerema
 
NA
Sather
 
HN
Sensel
 
MG
et al
Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group.
J Clin Oncol.
16
1998
1270
1278
11
Amylon
 
MD
Shuster
 
J
Pullen
 
J
et al
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group Study.
Leukemia.
13
1999
335
342
12
Mitelman
 
F
ISCN 1995: An International System for Human Cytogenetic Nomenclature.
1995
S. Karger
Basel, Switzerland
13
Peto
 
R
Pike
 
MC
Armitage
 
P
et al
Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples.
Br J Cancer.
35
1977
1
39
14
Cox
 
DR
Regression models and life tables.
J Royal Stat Soc B.
34
1972
187
202
15
Kaplan
 
EL
Meier
 
P
Nonparametric estimation from incomplete observations.
J Am Stat Assoc.
53
1958
457
481
16
Groupe Français de Cytogenetique Hematologique
Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Groupe Français de Cytogenetique Hematologique.
Blood.
87
1996
3135
3142
17
Raimondi
 
SC
Behm
 
FG
Roberson
 
PK
et al
Cytogenetics of childhood T-cell leukemia.
Blood.
72
1988
1560
1566
18
Groupe Français de Cytogenetique Hematologique
Collaborative study of karyotypes in childhood acute lymphoblastic leukemias.
Leukemia.
7
1993
10
19
19
Berger
 
R
Le Coniat
 
M
Vecchione
 
D
Derre
 
J
Chen
 
SJ
Cytogenetic studies of 44 T-cell acute lymphoblastic leukemias.
Cancer Genet Cytogenet.
44
1990
69
75
20
Kaneko
 
Y
Frizzera
 
G
Shikano
 
T
Kobayashi
 
H
Maseki
 
N
Sakurai
 
M
Chromosomal and immunophenotypic patterns in T cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL).
Leukemia.
3
1989
886
892
21
Gladstone
 
B
Amare
 
PS
Pai
 
SK
et al
Cytogenetic studies in patients from India with T-acute lymphoblastic leukemia.
Cancer Genet Cytogenet.
106
1998
44
48
22
Secker-Walker
 
LM
Campana
 
D
Hawkins
 
JM
Sampson
 
RE
Coustan-Smith
 
E
Karyotype and T-cell receptor expression in T-lineage acute lymphoblastic leukemia.
Genes Chromosomes Cancer.
4
1992
41
45
23
Uckun
 
FM
Gajl-Peczalska
 
KJ
Provisor
 
AJ
Heerema
 
NA
Immunophenotype-karyotype associations in human acute lymphoblastic leukemia.
Blood.
73
1989
271
280
24
Rowley
 
J
Reshmi
 
S
Carlson
 
K
Roulston
 
D
Spectral karyotype analysis of T-cell acute leukemia.
Blood.
93
1999
2038
2042
25
Hayashi
 
Y
Raimondi
 
SC
Look
 
AT
et al
Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia.
Blood.
76
1990
1626
1630
26
Pettenati
 
MJ
Rao
 
N
Wofford
 
M
et al
Presenting characteristics of trisomy 8 as the primary cytogenetic abnormality associated with childhood acute lymphoblastic leukemia: a Pediatric Oncology Group (POG) study (8600/8493).
Cancer Genet Cytogenet.
75
1994
6
10
27
Angioni
 
A
Ruscio
 
C
Giovannelli
 
L
et al
Characterization of a new case of trisomy 8 in acute lymphoblastic leukemia.
Cancer Genet Cytogenet.
74
1994
144
146
28
Huret
 
JL
Brizard
 
A
Slater
 
R
et al
Cytogenetic heterogeneity in t(11;19) acute leukemia: clinical, hematological and cytogenetic analyses of 48 patients—updated published cases and 16 new observations.
Leukemia.
7
1993
152
160
29
Murphy
 
SB
Raimondi
 
SC
Rivera
 
GK
et al
Nonrandom abnormalities of chromosome 9p in childhood acute lymphoblastic leukemia: association with high-risk clinical features.
Blood.
74
1989
409
415
30
Cayuela
 
JM
Madani
 
A
Sanhes
 
L
Stern
 
MH
Sigaux
 
F
Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia.
Blood.
87
1996
2180
2186
31
Theodossiou
 
C
Scalise
 
A
Troy
 
K
Silverman
 
L
Perdahl-Wallace
 
E
Najfeld
 
V
del(5q) in acute lymphoblastic leukemia with biphenotypic and early progenitor phenotype.
Cancer Genet Cytogenet.
63
1992
89
94
32
Whitlock
 
JA
Raimondi
 
SC
Harbott
 
J
et al
t(5;14)(q33–34;q11), a new recurring cytogenetic abnormality in childhood acute leukemia.
Leukemia.
8
1994
1539
1543
33
Smith
 
SD
Morgan
 
R
Gemmell
 
R
et al
Clinical and biologic characterization of T-cell neoplasias with rearrangements of chromosome 7 band q34.
Blood.
71
1988
395
402
34
Garcia
 
IS
Kaneko
 
Y
Gonzalez-Sarmiento
 
R
et al
A study of chromosome 11p13 translocations involving TCR beta and TCR delta in human T cell leukaemia.
Oncogene.
6
1991
577
582
35
Kwong
 
YL
Shing
 
MK
Wan
 
TM
et al
Inversion (14)(q11q32) in childhood T-cell acute lymphoblastic leukemia.
Cancer Genet Cytogenet.
72
1994
92
95
36
Wilkinson
 
A
Walker
 
DA
Smith
 
NM
Calvert
 
A
Monk
 
AJ
Parkin
 
CA
Inversion (14)(q11q32) in a patient with childhood T-cell acute lymphoblastic leukemia.
Cancer Genet Cytogenet.
88
1996
76
79
37
Takasaki
 
N
Kaneko
 
Y
Maseki
 
N
Sakurai
 
M
Shimamura
 
K
Takayama
 
S
Hemophagocytic syndrome complicating T-cell acute lymphoblastic leukemia with a novel t(11;14)(p15;q11) chromosome translocation.
Cancer.
59
1987
424
428
38
Silva
 
ML
de Oliveira
 
MS
Valente
 
AN
et al
CD7+, CD4-/CD8-acute leukemia with t(11;14)(p15;q11) in a child.
Cancer Genet Cytogenet.
56
1991
171
176
39
Carbone
 
P
Barbata
 
G
Tumminello
 
P
Bellanca
 
F
Majolino
 
I
Granata
 
G
Translocation t(8;14)(q24;q32) and del(1)(p22) in FAB-L1 adult acute lymphoblastic leukemia with long survival.
Cancer Genet Cytogenet.
32
1988
143
147
40
Pui
 
CH
Williams
 
DL
Raimondi
 
SC
et al
Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia.
Blood.
70
1987
247
253
41
Shikano
 
T
Ishikawa
 
Y
Ohkawa
 
M
et al
Karyotypic changes from initial diagnosis to relapse in childhood acute leukemia.
Leukemia.
4
1990
419
422
42
Kowalczyk
 
JR
Sandberg
 
AA
Anomalies of chromosome 1 as a possible prognostic index in childhood acute lymphoblastic leukemia.
Cancer Genet Cytogenet.
15
1985
303
308
43
Dreazen
 
O
Klisak
 
I
Jones
 
G
Ho
 
WG
Sparkes
 
RS
Gale
 
RP
Multiple molecular abnormalities in Ph1 chromosome positive acute lymphoblastic leukaemia.
Br J Haematol.
67
1987
319
324
44
Pui
 
CH
Behm
 
FG
Raimondi
 
SC
et al
Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia.
N Engl J Med.
321
1989
136
142
45
Childs
 
CC
Hirsch-Ginsberg
 
C
Culbert
 
SJ
et al
Lineage heterogeneity in acute leukemia with the t(4;11) abnormality: implications for acute mixed lineage leukemia.
Hematol Pathol.
2
1988
145
157
46
Heerema
 
NA
Palmer
 
CG
Weetman
 
R
Bertolone
 
S
Cytogenetic analysis in relapsed childhood acute lymphoblastic leukemia.
Leukemia.
6
1992
185
192
47
Pakkala
 
S
Knuutila
 
S
Helminen
 
P
Ruutu
 
T
Saarinen
 
UM
Peltonen
 
L
DNA-fingerprint changes compared to karyotypes in acute leukemia.
Leukemia.
4
1990
866
870
48
Pollak
 
C
Hagemeijer
 
A
Abnormalities of the short arm of chromosome 9 with partial loss of material in hematological disorders.
Leukemia.
1
1987
541
548
49
Liu
 
Y
Hermanson
 
M
Grander
 
D
et al
13q deletions in lymphoid malignancies.
Blood.
86
1995
1911
1915
50
Johnson
 
DD
Dewald
 
GW
Pierre
 
RV
Letendre
 
L
Silverstein
 
MN
Deletions of chromosome 13 in malignant hematologic disorders.
Cancer Genet Cytogenet.
18
1985
235
241
51
Juliusson
 
G
Merup
 
M
Cytogenetics in chronic lymphocytic leukemia.
Semin Oncol.
25
1998
19
26
52
Menasce
 
LP
Orphanos
 
V
Santibanez-Koref
 
M
Boyle
 
JM
Harrison
 
CJ
Deletion of a common region on the long arm of chromosome 6 in acute lymphoblastic leukaemia.
Genes Chromosomes Cancer.
10
1994
26
29
53
Merup
 
M
Moreno
 
TC
Heyman
 
M
et al
6q deletions in acute lymphoblastic leukemia and non-Hodgkin's lymphomas.
Blood.
91
1998
3397
3400
54
Thandla
 
S
Aplan
 
PD
Molecular biology of acute lymphocytic leukemia.
Semin Oncol.
24
1997
45
56
55
Ferrara
 
F
Scognamiglio
 
M
Di Noto
 
R
et al
Interstitial 9q deletion is associated with CD7+ acute leukemia of myeloid and T lymphoid lineage.
Leukemia.
10
1996
1990
1992
56
Kumon
 
K
Kobayashi
 
H
Maseki
 
N
et al
Mixed-lineage leukemia with t(10;11)(p13;q21): an analysis of AF10-CALM and CALM-AF10 fusion mRNAs and clinical features.
Genes Chromosom Cancer.
25
1999
33
39
57
Bernard
 
O
Groettrup
 
M
Mugneret
 
F
Berger
 
R
Azogui
 
O
Molecular analysis of T-cell receptor transcripts in a human T-cell leukemia bearing a t(1;14) and an inv(7): cell surface expression of a TCR-β chain in the absence of α chain.
Leukemia.
7
1993
1645
1653
58
Fizzotti
 
M
Chen
 
E
Link
 
M
et al
Simultaneous expression of RBTN-2 and BCR-ABL oncogenes in a T-ALL with a t(11;14)(p13;q11) and a late-appearing Philadelphia chromosome.
Leukemia.
8
1994
1124
1130
59
Kazmierczak
 
B
Dal Cin
 
P
Wanschura
 
S
Bartnitzke
 
S
Van den Berghe
 
H
Bullerdiek
 
J
Cloning and molecular characterization of part of a new gene fused to HMGIC in mesenchymal tumors.
Am J Pathol.
152
1998
431
435
60
Chase
 
A
Reiter
 
A
Burci
 
L
et al
Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12).
Blood.
93
1999
1025
1031
61
Hardingham
 
JE
Peters
 
GB
Dobrovic
 
A
et al
A rare translocation (4;11)(q21;p14–15) in an acute lymphoblastic leukemia expressing T-cell and myeloid markers.
Cancer Genet Cytogenet.
56
1991
255
262
62
Diaz
 
MO
Rubin
 
CM
Harden
 
A
et al
Deletions of interferon genes in acute lymphoblastic leukemia.
N Engl J Med.
322
1990
77
82

Author notes

Nancy R. Schneider, Pediatric Oncology Group, 645 N. Michigan Avenue, Suite 910, Chicago, IL 60611.

Sign in via your Institution